Showing 5061-5070 of 10638 results for "".
Improving CKD Patient Outcomes with SGLT2 Inhibitors
https://reachmd.com/programs/clinicians-roundtable/improving-ckd-patient-outcomes-with-sglt2-inhibitors/17943/How are SGLT2 inhibitors helping patients with CKD? Tune in.Shedding Light on the Brain After COVID-19: Assessing the Spectrum of Neurological Risk
https://reachmd.com/programs/neurofrontiers/shedding-light-on-the-brain-after-covid-19-assessing-the-spectrum-of-neurological-risk/12295/What are some of the neurological symptoms of COVID-19?The Medical System in Ghana: Key Roles for Physician Assistants
https://reachmd.com/programs/focus-on-global-medicine/the-medical-system-in-ghana-key-roles-for-physician-assistants/5789/In the past 40 years Medical Assistants have become a crucial part of Ghana's healthcare system. The MAs as their called are the equivalent to PAs in the U.S. For the past 40 years the 500 Medical Assistants have been trained at the Kintampo Rural Health Training School. Dr. Emmanuel Teye AdjaseThyroid Cancer Detection
https://reachmd.com/programs/clinicians-roundtable/thyroid-cancer-detection/2125/Thyroid cancer has traditionally been difficult to accurately diagnose and re-detect in the case of a recurrence. Why is it so difficult to diagnose and have we made further progress in the ability to better identify the markers of thyroid cancer? Dr. Allan Siperstien of Cleveland Clinic FoundationUrinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
https://reachmd.com/programs/project-oncology/ctdna-muscle-invasive-bladder-cancer-niagara-data/36310/Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulatingctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
https://reachmd.com/programs/project-oncology/ctdna-guided-bladder-preservation-mibc/36309/Emerging evidence is redefining bladder preservation strategies in muscle-invasive bladder cancer, with circulating tumor DNA (ctDNA) offering a novel approach to response-adapted care. Joining Dr. Charles Turck to review findings from the phase II RETAIN trials, which highlight how ctDNA clearanceDoes BMI Matter in mBC Outcomes?
https://reachmd.com/programs/project-oncology/does-bmi-matter-in-mbc-outcomes/49190/Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
https://reachmd.com/programs/project-oncology/ribosome-maturation-triple-negative-breast-cancer/48768/Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotlights research presented at the San Antonio Breast Cancer Symposium that implicaInfantile Epilepsy Effectively Treated With Off-Label Anticonvulsant
https://reachmd.com/programs/practical-neurology/infantile-epilepsy-effectively-treated/49204/Understanding Wound Dressing Innovations: From Basics to Advanced Therapies
https://reachmd.com/programs/clinicians-roundtable/understanding-wound-dressing-innovations-from-basics-to-advanced-therapies/36430/Wound care has evolved significantly, with a wide range of dressing types tailored to wound complexity. Hear from Dr. Geoffrey Gurtner as he explores the full spectrum, from inert and moisture-retentive dressings to advanced options like amniotic membranes and negative pressure wound therapy.